Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Advancing Care in Pediatric Plaque Psoriasis: Emerging Treatments and Management Strategies : Episode 7
Opinion
Video
Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis
Author(s):
Key Takeaways
- Roflumilast is used for COPD, reducing exacerbations but may cause gastrointestinal side effects.
- Apremilast is indicated for psoriatic arthritis and plaque psoriasis, with a favorable safety profile.
Panelists discuss how the two approved PDE4 inhibitors for pediatric plaque psoriasis differ in their systemic treatments, highlighting key differences in efficacy, safety profiles, and patient considerations for optimal use.
Video content above is prompted by the following:
- Currently there are two approved PDE4 inhibitors in this category. Could you provide an overview of these systemic treatments, highlighting their key differences and considerations in terms of efficacy and safety?
Related Videos
Related Content
